A single course of anti-muCD52 provided long-term therapeutic benefits in three animal models of MS reflecting different aspects of disease pathogenesis [81]: Chronic experimental autoimmune encephalomyelitis (EAE) induced by MOG35–55 (myelin oligodendrocyte glycoprotein) in C57BL/6 mice primarily driven by peptide-specific CD4+ T cells; MOG1–121 EAE with T and B cell dependent pathology; and PLP139–151 EAE in SJL mice mimicking a relapsing-remitting disease course [86]. The gene discussed is CD4; the disease is myeloid sarcoma.